B-cell CLL/lymphoma 11B (BCL11B) is a gene that encodes a C2H2-type zinc finger protein that functions as a transcriptional repressor. Fusions, missense mutations, nonsense mutations, silent mutations, frameshift insertions and deletions, and in-frame deletions are observed in cancers such as intestinal cancer, skin cancer, and stomach cancer.
BCL11B is altered in 0.98% of all cancers with lung adenocarcinoma, melanoma, colon adenocarcinoma, endometrial endometrioid adenocarcinoma, and diffuse large B-cell lymphoma, not otherwise specified having the greatest prevalence of alterations .
The most common alterations in BCL11B are BCL11B S765L (0.13%), BCL11B R620C (0.06%), BCL11B Amplification (0.03%), BCL11B E430K (0.04%), and BCL11B E535D (0.06%) .
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.